---
title: "Peptide capacity race: how GLP-1 is reshaping supply"
publisher: "Share Talk"
author: "sharetalk"
published: "2026-11-03T15:16:26+00:00"
modified: "2026-11-03T15:16:26+00:00"
date: 2026-11-03
canonical: "https://www.share-talk.com/peptide-capacity-race-how-glp-1-is-reshaping-supply/"
category: "Blogs"
categories: ["Blogs", "Business & Support Services", "Health", "Healthcare"]
tags: ["biotechs", "chemists", "Clinical development", "drugmakers", "GLP-1", "GLP-1 medicines", "medicines", "research peptide supplier", "Samsung Biologics"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/11/peptide-capacity-race-glp1-infographic.png?fit=1672%2C941&quality=80&ssl=1"
format: "news"
language: "en-GB"
---

# Peptide capacity race: how GLP-1 is reshaping supply

**Published:** November 3, 2026
**Author:** sharetalk
**Categories:** Blogs, Business & Support Services, Health, Healthcare
**Tags:** biotechs, chemists, Clinical development, drugmakers, GLP-1, GLP-1 medicines, medicines, research peptide supplier, Samsung Biologics
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/11/peptide-capacity-race-glp1-infographic.png?fit=1672%2C941&quality=80&ssl=1)

---

### The peptide capacity race: how GLP-1 demand is reshaping the supply chain from factory floor to lab bench

Ten years ago, peptide manufacturing was a specialist corner of the pharmaceutical industry. GLP-1 medicines have turned it into something much closer to heavy industry. Contract manufacturers are pouring billions into new plants, drugmakers are paying upfront for capacity they will not use until the next decade, and the suppliers serving early-stage labs are growing too. What investors are looking at is long-term demand running the full length of the chain.

### From kilograms to tonnes

For decades this was small-batch work. Picture a hormone analogue for a rare endocrine disorder: a few kilograms of active ingredient might cover a whole year’s demand, and factories were sized for exactly that. The field never stood still, though. A review in *Nature Reviews Drug Discovery*, one of the most cited on the subject, counted more than 80 peptide medicines on the market at the start of the 2020s, with around double that number working their way through clinical trials.

Then the GLP-1 drugs arrived and the numbers stopped looking small. In a KFF poll published in November 2025, 12% of American adults said they were currently taking one – twice the share of 18 months earlier. Treating that many people takes active ingredient by the hundreds of kilograms, and more and more often by the tonne.

Most chemists first meet solid-phase peptide synthesis as a bench technique. Running it in a factory is a different proposition. When member companies of the ACS Green Chemistry Institute Pharmaceutical Roundtable shared their process data, the figure that came out was striking: roughly 13,000 kg of solvents and reagents for each kilogram of finished peptide, many times what a standard small-molecule route needs. That is exactly where a lot of the new money is going – greener solvents, hybrid synthesis routes and purification that wastes less.

### The billions being committed

The big contract development and manufacturing organisations (CDMOs) have answered with some of the largest capital programmes the sector has ever seen. A selection:

![](https://www.share-talk.com/wp-content/uploads/2026/11/peptide-cdmo-investments-table-300x169.png)

What stands out is the sheer size of these projects. They are whole plants built for industrial volumes rather than an extra reactor here and there, and nobody commits to a build lasting the best part of a decade without confidence in demand at the far end of it. Novo Nordisk and Eli Lilly have spent on a similar scale in their own networks, so outsourced and in-house capacity are rising together.

### Consolidation as a signal

Samsung Biologics made its intentions plain in July 2026 with an all-cash offer for PolyPeptide Group at CHF 44.31 a share. That values the Swiss peptide specialist at about CHF 1.46bn, or roughly $1.8bn. PolyPeptide’s board backed the bid, its largest shareholder agreed to tender a stake of around 56%, and the deal is expected to complete towards the end of the year. Samsung built its business on antibodies and other biologics; buying PolyPeptide gives it a serious peptide operation in a single move.

Look at how new capacity is being sold and the confidence is just as clear. Bachem’s Sisslerfeld plant rests on a supply agreement in which the customer makes upfront payments towards construction and signs up for the long term, even though commercial output will not start until 2030. Customers are paying now for production at the end of the decade, which gives manufacturers a rare degree of visibility on future revenue.

### Beyond GLP-1

Incretin drugs supply the volume, but plenty else is filling the pipeline. The next generation of metabolic candidates hits several receptors at once: retatrutide, which acts on three gut-hormone receptors, produced substantial weight loss over 48 weeks in a phase 2 trial reported in the *New England Journal of Medicine*. Outside metabolic disease the list keeps getting longer, taking in cancer, infections and rare disorders. Better discovery tools, display libraries above all, mean chemists can find tight-binding sequences in a fraction of the time it used to take.

Peptide-drug conjugates are one corner of this that the market follows with particular interest. The concept will be familiar from antibody-drug conjugates – a targeting element carries a powerful payload to where it is needed – only here the carrier is a peptide, a fraction of the size. Smaller carriers tend to get deeper into tumours, and they are easier to make. A review from the University of Cambridge in *Chemical Society Reviews* lays out the case in detail. AIM has a home-grown example in Avacta (AIM: AVCT). Its pre|CISION platform attaches a drug to a peptide that a tumour-associated enzyme cuts, releasing the payload inside the tumour. The US FDA cleared the company’s second-generation candidate, AVA6103, for clinical testing in January 2026, and the first patient received it in March.

For the supply chain, what matters is breadth. Demand now comes from many kinds of molecule and many disease areas, so the industry’s growth does not rest on any one drug class.

### Every tier of the chain is scaling

The giant plants get the headlines, but peptide supply works in layers, and all of them are growing:

- **Commercial API.** GMP production of active ingredients for approved medicines, by the hundreds of kilograms or the tonne. Most of the francs and euros in the table above end up here.

- **Clinical development.** Process development and smaller GMP batches for biotechs moving candidates through phases 1 to 3. Bachem’s clinical-stage business grew in 2024 on the strength of peptide development projects.

- **Discovery.** Long before any of that, university and industry labs are screening sequences, testing analogues and building cell and animal models. Their catalogue and custom peptides come from a specialist [research peptide supplier](https://puritapeptides.com/), and that material is made for in vitro and preclinical work only, not for use in people.

By revenue the discovery layer is the smallest, and it is easy to forget about. It is also where every future medicine begins. A new peptide can often be made in a matter of days, whereas some natural products take months or years to synthesise, so ideas get tested quickly. The more candidates that enter at this end, the healthier the flow that eventually reaches the commercial plants.

### Documentation as the new currency

Bigger volumes make the records behind each batch more important, not less. Synthetic peptides can carry impurities that look a lot like the real thing – sequences with a residue missing, chains cut short, protecting groups left behind – so analytical testing sits at the heart of peptide quality control. A certificate of analysis confirming identity by mass spectrometry, purity by HPLC and the endotoxin level has become the minimum expected at every level, from commercial API to the vial on a lab shelf.

Regulators are moving the same way. HHS, the US health department, put out a draft policy in October 2026 covering six peptides that compounding pharmacies use. Pharmacies that want to work with them will need GMP material from an FDA-registered manufacturer, plus a certificate for every lot showing identity, purity, potency, endotoxins and heavy metals. None of this applies to research suppliers. Still, there is now a public, written description of what proper documentation is expected to look like.

For labs, all this paperwork buys something valuable: results other people can trust. If the contents of a vial are fully characterised, another group can repeat the work or build on it. Investors should read it as a moat. Strong analytical teams and lot-by-lot traceability take years to put together, and a rival cannot simply buy them off the shelf.

### What investors should watch

- **New capacity coming on stream.** Much of what was announced in 2024 and 2025 is being commissioned now or will be next year; Bachem’s Sisslerfeld site comes later, in 2030. Watch the start-up dates and the utilisation figures – they will tell you when all this new kit starts paying its way.

- **The steps after synthesis.** More API is only half the job. Sterile fill-finish and pen-injector assembly are getting their own wave of investment, and they will go a long way towards deciding how quickly finished products get to patients.

- **The PolyPeptide deal.** Completion of Samsung Biologics’ offer, expected around the turn of the year, will be the clearest guide yet to what buyers will pay for peptide manufacturing know-how.

- **Regulators on both sides of the Atlantic.** The final HHS policy, FDA rulemaking on compounding lists and MHRA decisions on new peptide medicines will all shape where demand goes.

- **Trial results.** Phase 3 data for multi-agonist metabolic drugs and early readouts from peptide-drug conjugate programmes, Avacta’s AVA6103 among them, will show which parts of the pipeline drive the next wave of volume.

**References**

**Scientific literature**

1. [Trends in peptide drug discovery](https://doi.org/10.1038/s41573-020-00135-8) – Muttenthaler et al., *Nature Reviews Drug Discovery*, 2021

2. [Process mass intensity (PMI): a holistic analysis of current peptide manufacturing processes](https://doi.org/10.1021/acs.joc.3c01494) – Kekessie et al., *Journal of Organic Chemistry*, 2024

3. [Sustainability challenges in peptide synthesis and purification: from R&D to production](https://doi.org/10.1021/acs.joc.8b03001) – Isidro-Llobet et al., *Journal of Organic Chemistry*, 2019

4. [Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial](https://doi.org/10.1056/NEJMoa2301972) – Jastreboff et al., *New England Journal of Medicine*, 2023

5. [Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates](https://doi.org/10.1039/D0CS00556H) – Cooper et al., *Chemical Society Reviews*, 2021

6. [Related impurities in peptide medicines](https://doi.org/10.1016/j.jpba.2014.06.012) – D’Hondt et al., *Journal of Pharmaceutical and Biomedical Analysis*, 2014

**Primary industry and regulatory sources**

1. [KFF Health Tracking Poll: prescription drug costs and GLP-1 use](https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/) – KFF, November 2025

2. [Samsung Biologics announces all-cash offer to acquire PolyPeptide](https://samsungbiologics.com/media/company-news/samsung-biologics-announces-all-cash-offer-to-acquire-polypeptide) – Samsung Biologics, July 2026

3. [Bachem plans to build a large-scale production facility](https://chemanager-online.com/en/news/bachem-plans-to-build-a-large-scale-production-facility) – CHEManager, July 2026

4. [Bachem Annual Report 2025](https://www.bachem.com/wp-content/uploads/2026/03/Bachem-Annual-report-2025-DE.pdf) – Bachem, March 2026

5. [CordenPharma strikes deal for peptide CDMO](https://www.fiercepharma.com/manufacturing/glp-1-manufacturer-cordenpharma-strikes-deal-peptide-cdmo-lining-new-production-sites) – Fierce Pharma

6. [CDMO/CMO expansion update: riding the strength of TIDES](https://www.dcatvci.org/features/cdmo-cmo-expansion-update-riding-the-strength-of-tides) – DCAT Value Chain Insights

7. [Neuland Laboratories to open Hyderabad commercial peptide facility](https://www.europeanpharmaceuticalreview.com/news/neuland-laboratories-to-open-hyderabad-commercial-peptide-facility/1132047.article) – European Pharmaceutical Review

8. [Avacta interim results for the six months to 30 June 2026](https://capital.com/en-eu/news/avacta-group-plc-interim-results-for-the-six-months-to) – Avacta Group plc, September 2026

9. [HHS draft policy eases enforcement on 6 compounded peptides](https://www.ajmc.com/view/hhs-draft-policy-eases-enforcement-on-6-compounded-peptides) – AJMC, October 2026

---

**Original URL:** https://www.share-talk.com/peptide-capacity-race-how-glp-1-is-reshaping-supply/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*